Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! (Q38179975)

30 August 2017

title

Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! (English)

1 reference

30 August 2017

1 reference

M A Kharfan-Dabaja

1

1 reference

30 August 2017

M Hamadani

series ordinal

2

1 reference

30 August 2017

H Sibai

series ordinal

3

1 reference

30 August 2017

B N Savani

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

20 January 2014

1 reference

Bone Marrow Transplantation

30 August 2017

published in

1 reference

30 August 2017

volume

49

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

599-606

1 reference

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Advances in the treatment of relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Does rituximab have a place in treating classic hodgkin lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Second autologous stem cell transplant for multiply relapsed Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.226

Pharmaceutical approval update

21 January 2018

1 reference

12 December 2020

Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens

1 reference

12 December 2020

Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry

2 references

12 December 2020

https://api.crossref.org/works/10.1038%2FBMT.2013.226

7 January 2021

inferred from DOI database lookup

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

1 reference

12 December 2020

Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up

1 reference

12 December 2020

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia

1 reference

12 December 2020

High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant

1 reference

12 December 2020

New drugs in the treatment of Hodgkin's disease

1 reference

12 December 2020

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

1 reference

12 December 2020

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

12 December 2020

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

1 reference

12 December 2020

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

1 reference

12 December 2020

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

12 December 2020

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

1 reference

12 December 2020

Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect

1 reference

12 December 2020

Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2013.226

1 reference

Dimensions Publication ID

30 August 2017

1045888615

0 references

1 reference